17-hydroxyprogesterone: The Steroid That Backs Up Behind a Blocked Enzyme

Understand what your hormone testing results really mean

See your biomarkers in context with a comprehensive panel.

• CLIA-certified labs
• HIPAA compliant
• Personalized health protocol

Book your test

17-Hydroxyprogesterone, defined in plain physiological terms

17-hydroxyprogesterone (17-OHP) is a steroid hormone made mostly in the adrenal glands, with smaller amounts from the ovaries and testes. It sits midstream in the steroid assembly line, downstream from progesterone and upstream from cortisol. A rising 17-OHP usually means traffic is backing up on the road to cortisol, most often because the enzyme 21-hydroxylase is sluggish. A low value more often reflects low adrenal drive or suppression from medication.

The names that all mean 17-OHP, and one that does not

17-OHP, 17-OH progesterone, 17α-hydroxyprogesterone, and 17-hydroxyprogesterone are four names for one analyte, so a report using any of them refers to the same measurement. Two neighbors are genuinely different molecules: progesterone sits one step upstream and is measured to confirm ovulation, and 17-hydroxypregnenolone belongs to the parallel Δ5 branch.

One near-identical name is a different substance entirely. 17-hydroxyprogesterone caproate is an injectable synthetic progestin once approved to reduce preterm birth risk and withdrawn from the US market in 2023, not a hormone the body makes and not what this blood test measures.

The adrenal and ovarian biology behind 17-OHP

Picture steroid hormones as a branching subway map. Cholesterol enters the station, enzymes shuttle it through junctions, and the route splits toward cortisol, aldosterone, and androgens. 17-OHP sits at a key transfer point. When 21-hydroxylase is functioning normally, 17-OHP moves toward cortisol. When that enzyme is partially blocked, 17-OHP piles up and leaks into androgens like androstenedione and testosterone. One caveat: 17-OHP is not a stand-in for circulating cortisol. It reflects the upstream precursor load, not the final output.

Stress pushes the accelerator. When the brain senses stress, ACTH rises, the adrenal cortex revs, and 17-OHP climbs alongside cortisol precursors. The hormone also follows a circadian rhythm, which is why sampling before 8 am is the standard, and in people who menstruate it sits lower in the follicular phase than in the luteal phase.

Those swings are physiology, not pathology, which is why patterns and standardized timing beat snap judgments on a single draw.

What a 17-OHP test measures and why it gets ordered

A 17-OHP test measures the concentration of 17-hydroxyprogesterone in serum, reported in ng/dL in the United States and nmol/L elsewhere. It is not a general wellness screen. The test answers one focused question: is the pathway toward cortisol running cleanly, or is precursor backing up behind the 21-hydroxylase step?

Four situations account for most testing: newborn screening programs, which use 17-OHP as the primary screening analyte for 21-hydroxylase deficiency; androgen symptoms in teens and adults; fertility workups where cycles are irregular; and monitoring in someone already known to have congenital adrenal hyperplasia (CAH).

Who gets tested, by life stage

• Newborns. Tested automatically through state screening programs, usually from a heel-stick dried blood spot in the first days of life.
• Children and teens. Tested when growth accelerates early, body hair arrives ahead of schedule, or puberty starts unusually young.
• Women. Tested when hirsutism, persistent acne, irregular cycles, or trouble conceiving raise the question of androgen excess.
• Men. Tested less often, typically alongside a fertility workup or when an adrenal finding needs explaining.

Join 150,000+ others building better health

Get the science behind better health, every week.

SubscribeSigning up...

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Thanks for signing up!

Check your inbox — your first issue is on the way. We send clinically reviewed health science, never spam.

Reading your 17-hydroxyprogesterone number in context

A 17-OHP result is read against age, sex, menstrual phase, pregnancy status, and the assay the lab ran, which is why a number without those conditions attached is hard to interpret. The same serum can return meaningfully different values on an immunoassay versus LC-MS/MS.

"Normal" here describes where most people in a reference population fall on that lab's assay. It is a population reference, not an optimal target, and for 17-OHP the distinction cuts a specific way: the action threshold that prompts evaluation for CAH is defined against a morning, follicular-phase draw, not against the wider interval a lab prints to cover every cycle phase.

17-OHP reference ranges by age, sex, and cycle phase

An adult woman tested in the morning during the follicular phase typically has a value well below 200 ng/dL (6 nmol/L), and a basal value at or above 200 ng/dL is where screening for nonclassic CAH usually begins. General values by age and sex look roughly like this:

| Group | Typical value (ng/dL) | Typical value (nmol/L) | What shifts it | |---|---|---|---| | Newborn, more than 24 hours old | Below ~400 to 600 | Below ~12 to 18 | Values differ for low-birth-weight infants | | Newborn, preterm or unwell | Markedly higher | Markedly higher | Screening cutoffs adjusted for gestational age and birth weight | | Child before puberty | Around 100 | Around 3 | Rises through puberty | | Adult female | Below ~290 | Below ~8.8 | Lower in the follicular phase, higher after ovulation | | Adult male | Below ~139 | Below ~4.2 | Morning sampling, no cycle effect | | Pregnancy | Interpret separately | Interpret separately | Dips early, then rises toward term |

These intervals are lab- and assay-specific, and automated immunoassays run measurably differently from LC-MS/MS on the same serum, so read your value against the interval printed on your own report.

When levels run low

Low 17-OHP can look reassuring, and sometimes it is. It can reflect low ACTH drive, suppression from exogenous glucocorticoids, or well-controlled disease in someone with CAH. In adrenal insufficiency, 17-OHP may be low along with cortisol, but that finding alone is never enough to confirm it. Timing again matters: afternoon draws and follicular-phase draws both run lower. Assay method shifts the absolute number on top of that.

When levels are in range

A result within the reference range means the steroid pathway is moving traffic without an obvious bottleneck at the 21-hydroxylase step, with one caveat: a draw taken outside the morning follicular window can read normal even in nonclassic CAH. There is no defined "optimal" target inside that range: the value of 17-OHP lies in catching deviation, not in fine-tuning a normal number. Use it as a baseline and watch the pattern.

When levels run high

Elevated 17-OHP often signals a bottleneck in the cortisol pathway, and the classic cause is 21-hydroxylase deficiency, which spans a spectrum. Markedly high newborn values point toward classic CAH and warrant prompt specialist evaluation. Milder elevations in adolescents and adults may point to nonclassic CAH, where a basal morning value is often only modestly high and then climbs sharply after ACTH stimulation.

How high the number runs changes what it means:

• Up to 200 ng/dL (6 nmol/L) basal. A morning follicular value in this territory is unremarkable on its own and rarely triggers further hormonal evaluation.
• Roughly 200 to 1,000 ng/dL (6 to 30 nmol/L) basal. The gray zone. Values at or above 200 ng/dL typically lead to an ACTH stimulation test to separate a real enzyme bottleneck from timing, cycle phase, or assay effects.
• Above 1,000 ng/dL (30 nmol/L) after stimulation. A stimulated value in this range supports nonclassic 21-hydroxylase deficiency.

But not every bump equals disease. The luteal phase, normal circadian variation, acute stress, recent illness, and assays that cross-react with related steroids all lift the number without an enzyme block behind it. A mildly high value is why the recheck exists: repeat in the morning, in the follicular phase, and ideally on LC-MS/MS when the question is CAH. A repeat elevation paired with androstenedione, testosterone, and clinical signs tells a far clearer story than a one-off spike.

Classic and nonclassic CAH, side by side

Both forms come from 21-hydroxylase deficiency, and the difference is how much enzyme activity survives. Classic CAH appears at birth or in infancy, with 17-OHP running very high on the newborn screen and a risk of salt wasting and adrenal crisis that makes it a medical emergency.

Nonclassic CAH retains enough enzyme activity to protect cortisol and salt balance, so it surfaces later, in childhood, adolescence, or adulthood, as androgen excess rather than acute illness. Basal 17-OHP is mildly to moderately raised, and ACTH stimulation is what makes the pattern unmistakable.

Telling nonclassic CAH apart from PCOS

From the outside, nonclassic CAH and PCOS can look identical, and 17-OHP is the marker that separates them.

| What you compare | Nonclassic CAH | PCOS | |---|---|---| | How it presents | Hirsutism, acne, irregular cycles, subfertility | Hirsutism, acne, irregular cycles, subfertility | | Basal morning 17-OHP | Often at or above 200 ng/dL | Usually inside the reference interval | | Response to ACTH stimulation | Rises past 1,000 ng/dL | Stimulated value stays below the cutoff | | Typical age at presentation | Childhood through early adulthood | From adolescence onward | | What confirms it | Stimulated 17-OHP, CYP21A2 genotyping | Clinical criteria once other causes are excluded |

Why a 17-OHP result drifts between draws

17-OHP responds to both physiology and lab method, so several variables move the number while the underlying pathway stays exactly the same.

| Factor | Direction of effect | What to do about it | |---|---|---| | Circadian ACTH drive | Follows a predictable daily rhythm | Draw in the morning, every time | | Menstrual cycle phase | Higher in the luteal phase, lower in the follicular | Schedule the draw in the follicular phase | | Acute stress, illness, sleep debt | Transiently higher | Postpone the draw until you have recovered | | Intense training | ACTH and cortisol rise acutely, and 17-OHP can follow | Skip hard sessions the day before | | Glucocorticoid medication | Lower, through ACTH suppression | Expected in CAH care; note the dose on the requisition | | Hormonal contraceptives | Reduce adrenal androgen production | Record current use so the value is read in context | | Pregnancy | Dips early, then rises toward term | Interpret against pregnancy-specific intervals | | High-dose biotin | Unpredictable on some immunoassays | Pause biotin per your lab's instructions | | Assay platform | Different absolute values on the same serum | Keep the same lab and method across draws |

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your testLoading...

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your testLoading...

How a 17-OHP test is done and how to prepare

A 17-OHP test is a routine venous blood draw — a heel stick in newborns — and no fasting is required. Timing is the preparation that matters, because the conditions of the draw shape the number more than anything else you control.

1. Schedule the draw for early morning, ideally before 8 am, which is the window the screening thresholds were set against.
2. If you menstruate, schedule the follicular phase, around cycle days 2 to 5, when 17-OHP holds a low, stable level.
3. Pause high-dose biotin supplements for the interval your lab specifies, since biotin can distort some immunoassays.
4. Ask whether the lab runs immunoassay or LC-MS/MS, and request LC-MS/MS when the question is CAH.
5. Bring your medication list, especially glucocorticoids and hormonal contraceptives, so the result is read against what you are taking.

What to test alongside 17-hydroxyprogesterone for context

17-OHP rarely tells the full story alone. These markers, drawn together, locate where in the steroid pathway a signal starts and how far downstream it has traveled.

| Marker | What it adds | Pattern that matters | |---|---|---| | Cortisol | The downstream output of the same pathway | High 17-OHP with low cortisol supports a true 21-hydroxylase bottleneck | | DHEA-S | An adrenal-specific androgen | Normal DHEA-S with high androstenedione points at the 17-OHP branch, not a global adrenal surge | | Testosterone (total) | Measures downstream androgen output | Tracked with androstenedione in 21-hydroxylase deficiency; often high in women and children, while in men it mostly reflects testicular output | | FSH | Separates ovarian from adrenal drivers | Useful when cycles are irregular and the source is unclear | | LH | Complements FSH on ovulatory signaling | Adds ovulatory context when a PCOS-like pattern is in question |

A realistic retest window for your 17-OHP

The conditions of a retest matter as much as the interval. For people on glucocorticoid therapy in a CAH context, follow-up is set by a clinician rather than by a fixed rule: growing patients are typically evaluated every 3 to 4 months, and in adults hormone measurements are timed consistently relative to medication and time of day.

For anyone tracking a baseline or checking a mildly abnormal result, standardize every draw: same lab, same morning timing, same cycle phase. Same-condition draws are the only ones worth comparing, and a mid-series switch of assay platform can mimic a change that never happened.

What happens after an elevated 17-OHP result

An elevated 17-OHP is a starting point, not a conclusion, and the workup that follows is a defined sequence rather than a single test.

1. Repeat the draw under standardized conditions: early morning, follicular phase, same lab.
2. Confirm on LC-MS/MS if the first value came from an immunoassay, since cross-reacting steroids can inflate an immunoassay result.
3. Proceed to an ACTH stimulation test when the repeat basal value stays above the screening threshold.
4. Consider CYP21A2 genotyping, which identifies the specific 21-hydroxylase variants and informs family and reproductive planning.
5. Involve an endocrinologist for any markedly elevated result, any newborn screening flag, and any adult result that changes management.

The ACTH stimulation test, briefly

The ACTH stimulation test measures how much 17-OHP the adrenal glands release when they are deliberately pushed. Synthetic ACTH is given, and 17-OHP is measured at baseline and again 60 minutes after cosyntropin. A partly blocked 21-hydroxylase enzyme has nowhere to send the extra precursor, so it accumulates instead: stimulated values above 1,000 ng/dL (30 nmol/L) support nonclassic 21-hydroxylase deficiency, while a modest rise argues against it.

See your 17-hydroxyprogesterone with a Superpower hormone panel

Testing 17-OHP is about clarity and timing. In newborns, state screening programs are designed to catch classic CAH early. In teens and adults it can explain androgen symptoms that do not fit the usual patterns: acne, hirsutism, irregular cycles, and difficulty conceiving. The win comes from trending, not chasing single values.

A markedly elevated result at any age warrants prompt clinical evaluation, and a mildly elevated one deserves a standardized recheck before conclusions are drawn. A low result on glucocorticoid therapy is expected; a low result alongside symptoms of adrenal insufficiency deserves further workup.

Superpower builds testing around exactly that context: the surrounding hormones in the same draw, and a trend you can actually read. The Women's Core Hormones panel measures 17-hydroxyprogesterone alongside FSH, LH, progesterone, estradiol, and prolactin, so your number arrives with the pathway around it rather than on its own. 17-hydroxyprogesterone is measured by a laboratory-developed test validated under CLIA; it is not cleared or approved by the FDA, and results are used to aid clinician evaluation rather than as a stand-alone diagnosis. This article is for informational purposes only and does not constitute medical advice.